Menu

Interactive Infographic: The Global Business of Dying

Throughout the world, laws governing how terminally ill patients can choose to die vary widely.

Aug 16, 2017
Catherine Offord

Although in many parts of the world, the rules governing the legality of assisting in another person’s death are murky at best, some countries have passed legislation that explicitly allows doctors to aid in ending the lives of their patients—either by prescription of a lethal dose of drugs such as barbiturates (generally termed medical aid-in-dying in the U.S.) or by a clinician-administered lethal injection (often called euthanasia). In most, but not all, of these countries, the patient must be an adult, reside in the country where they receive end-of-life care, and have an incurable medical condition that causes them suffering. (Click the labeled countries for more information about their practices.) 

DEVELOPED BY KARL PAWLOWICZ

See U.S. map for an overview of practices by state.

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN Ltd are pleased to announce the commercial licensing of CRISPR-Cas9 gene-editing technology from Broad Institute of MIT and Harvard in the USA, to develop human cell disease models to support preclinical metabolic disease therapeutic programmes.